DigiBiomics is a Canadian health-tech company pioneering AI-powered diagnostics for the early detection and monitoring of respiratory diseases such as COPD, tuberculosis, pneumonia, and lung cancer. Our flagship platform, LungSense, leverages multimodal data including medical imaging, clinical history, and audio biomarkers (cough and breath sounds) to provide real-time risk assessment and triage support for clinicians and frontline workers. Accessible via mobile and tablet, LungSense is designed to function effectively even in resource-limited or remote settings, promoting equitable access to care.